Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023
Publication Date Sep 2014
Product Type Report
Pages 55
Single User License help $ 3495.00
Site User License help $ 6990.00
Corporate User License help $ 10485.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023”. HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third, and fourth-line metastatic.

GSK’s Tykerb (lapatinib ditosylate monohydrate) is a small-molecule inhibitor of the intracellular tyrosine kinase domain of EGFR and HER2. Tykerb was approved by the FDA in 2007, and by the European Medicines Agency (EMA) in 2008, for use in locally-advanced or metastatic breast cancer, in combination with Xeloda (capecitabine). In 2010, the FDA and EMA approved Tykerb for use in HR positive locally advanced or metastatic breast cancer in combination with letrozole.

Scope

- Overview of HER2-Positive Breast Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Tykerb including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Tykerb for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HER2-Positive Breast Cancer
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Tykerb performance
- Obtain sales forecast for Tykerb from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 12
3.2 Basic Breast Anatomy 14
3.3 Breast Cancer Staging 15
3.4 Prognosis 16
3.5 Quality of Life 17
3.6 Symptoms 19
4 Disease Management 20
4.1 Treatment Overview 20
4.1.1 Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB) 20
4.1.2 Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIA) 21
4.1.3 Treatment of Metastatic HER2-Positive Breast Cancer (Stage IV) 24
5 Competitive Assessment 27
5.1 Overview 27
6 Tykerb (lapatinib) 29
6.1 Overview 29
6.2 Efficacy 30
6.3 Safety 32
6.4 SWOT Analysis 32
6.5 Forecast 33
7 Appendix 34
7.1 Bibliography 34
7.2 Abbreviations 42
7.3 Methodology 45
7.4 Forecasting Methodology 45
7.4.1 Diagnosed HER2-Positive Breast Cancer Patients 45
7.4.2 Percent Drug-Treated Patients 46
7.4.3 General Pricing Assumptions 46
7.4.4 Individual Drug Assumptions 48
7.5 Primary Research - KOLs Interviewed for this Report 49
7.6 Primary Research - Prescriber Survey 51
7.7 About the Authors 52
7.7.1 Analyst 52
7.7.2 Therapy Area Director 52
7.7.3 Global Head of Healthcare 53
7.8 About GlobalData 54
7.9 Disclaimer 54

List of Tables
1.1 List of Tables
Table 1: AJCC Stage Definitions for Breast Cancer 16
Table 2: Prognosis for Breast Cancer in the US 17
Table 3: Treatment Guidelines for HER2-Positive Breast Cancer 26
Table 4: Product Profile - Tykerb 30
Table 5: Tykerb SWOT Analysis, 2013 32
Table 6: Global Sales Forecast ($m) for Tykerb, 2013-2023 33
Table 7: HER2-Positive Breast Cancer Incidence, 2013-2023 46
Table 8: Average Body Weight and Surface Area Across the 8MM 47
Table 9: Average Annual Cost of Therapy ($) - Tykerb, First Line 48
Table 10: Physicians Surveyed by Country 51

List of Figures
1.2 List of Figures
Figure 1: Basic Breast Anatomy, Including Key Lymph Nodes 14
Figure 2: Primary Completion Dates of Active Phase III Clinical Trials for Tykerb 29

Title Date Price
Europe Digital Camera Head for Endoscopes Industry 2016 Market Research Report
By QYResearch
The Europe Digital Camera Head for Endoscopes Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Digital Camera Head for Endoscopes industry. The re ...Read More
Apr 2016 $3600.00
China Pharmaceutical Guidebook Series (4) Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Traditional Chinese Medicines and Natural Medicines
By Access China Management Consulting Ltd
The traditional medicines in Orient, especially, the traditional Chinese medicines are always regarded by occidental as mysterious medicines. Until today not only the chemical composition of tradition ...Read More
May 2015 $750.00
Latest Guide to Chinese Pharmaceutical GMP Regulations
By Access China Management Consulting Ltd
China possesses a fourth population in the world and has one of the largest drug markets round the world. By 2012, sales on the Chinese drug market have reached RMB 926.1billion (about US$147 billion) ...Read More
Jul 2015 $750.00
"Acne vulgaris "- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Acne vulgaris  - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview of the disease and ...Read More
Apr 2016 $4950.00
"Acute coronary syndrome(ACS)"- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Acute coronary syndrome (ACS) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview of th ...Read More
Apr 2016 $4950.00
"Acute heart failure(AHF)"- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Acute heart failure (AHF) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview of the di ...Read More
Apr 2016 $4950.00
"Acute ischemic stroke (AIS)"- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Acute ischemic stroke (AIS) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview of the ...Read More
Apr 2016 $4950.00
"Acute lymphoblastic leukemia (ALL)"- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Acute lymphoblastic leukemia (ALL) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview ...Read More
Apr 2016 $4950.00
"Age-related macular degeneration (AMD)"- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Age-related macular degeneration (AMD) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overv ...Read More
Apr 2016 $4950.00
"Alzheimer’s disease (AD)"- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview of the d ...Read More
Apr 2016 $4950.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

Published By :  GlobalData

For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9893555190
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z